Baseline characteristics for patients in the PEGASUS study with and without hemolysis events
| . | Patients with hemolysis event (n = 19) . | Patients without hemolysis event (n = 61) . |
|---|---|---|
| Age, y | ||
| Mean (range) | 54.5 (28-78) | 47.0 (19-81) |
| >65, n (%) | 7 (37) | 10 (16) |
| Sex, n (%) | ||
| Female | 7 (37) | 42 (69) |
| Body mass index, mean (SD), kg/m2 | 27.5 (4.5) | 26.0 (4.2) |
| No transfusions in previous 12 mo, n (%) | 4 (21) | 16 (26) |
| ≥4 transfusions in previous 12 mo, n (%) | 13 (68) | 31 (51) |
| History of thrombosis, n (%) | 8 (42) | 17 (28) |
| On-label eculizumab dose at screening (900 mg every 2 wk), n (%) | 9 (47) | 47 (77) |
| Higher-than-label eculizumab dose at screening (>900 mg every 2 wk), n (%) | 10 (53) | 14 (23) |
| 1200 mg every 2 wk∗ | 9 (47) | 13 (21) |
| 1500 mg every 2 wks | 1 (5) | 1 (2) |
| Hb, mean (SD), g/dL | 8.8 (1.0) | 8.6 (1.0) |
| LDH, mean (SD), U/L | 305.6 (212.6) | 275.2 (211.7) |
| Complement CH50, mean (SD), U/mL | 19.7 (27.6) | 5.4 (16.0) |
| Detectable complement CH50, n (%) | 14 (74) | 33 (54) |
| . | Patients with hemolysis event (n = 19) . | Patients without hemolysis event (n = 61) . |
|---|---|---|
| Age, y | ||
| Mean (range) | 54.5 (28-78) | 47.0 (19-81) |
| >65, n (%) | 7 (37) | 10 (16) |
| Sex, n (%) | ||
| Female | 7 (37) | 42 (69) |
| Body mass index, mean (SD), kg/m2 | 27.5 (4.5) | 26.0 (4.2) |
| No transfusions in previous 12 mo, n (%) | 4 (21) | 16 (26) |
| ≥4 transfusions in previous 12 mo, n (%) | 13 (68) | 31 (51) |
| History of thrombosis, n (%) | 8 (42) | 17 (28) |
| On-label eculizumab dose at screening (900 mg every 2 wk), n (%) | 9 (47) | 47 (77) |
| Higher-than-label eculizumab dose at screening (>900 mg every 2 wk), n (%) | 10 (53) | 14 (23) |
| 1200 mg every 2 wk∗ | 9 (47) | 13 (21) |
| 1500 mg every 2 wks | 1 (5) | 1 (2) |
| Hb, mean (SD), g/dL | 8.8 (1.0) | 8.6 (1.0) |
| LDH, mean (SD), U/L | 305.6 (212.6) | 275.2 (211.7) |
| Complement CH50, mean (SD), U/mL | 19.7 (27.6) | 5.4 (16.0) |
| Detectable complement CH50, n (%) | 14 (74) | 33 (54) |
CH50, total complement function; Hb, hemoglobin; LDH, lactate dehydrogenase; SD, standard deviation.
One patient in the pegcetacoplan group received 900 mg of eculizumab every 11 days.